CAJ | 학술논문

目的观察B超及MRI在乳腺癌新辅助化疗疗效评价中的作用.方法对2007年7月至2008年7月接受新辅助化疗的85例原发性乳腺癌患者进行前瞻性研究,对比分析手术前新辅助化疗前、化疗2周期后、化疗4周期后患者的B超、MRI影像学资料,参照实体瘤疗效评价标准(RECIST)评价疗效,并与术后组织病理学检查进行比较.结果人组患者共85例,均完成4周期新辅助化疗.MRI评估完全缓解(CR)者0例,部分缓解(PR)者56例,疾病稳定(SD)者27例,疾病进展(PD)者2例;B超评估CR者0例,PR者52例,sD者31例,PD者2例.MRI及B超对新辅助化疗后残余肿瘤检测的阳性预测值均为94.1%.其中新辅助化疗后残余肿瘤最大径线MRI测茸结果与病理镜下测量结果高度相关(r=0.783,P<0.05),B超对残余肿瘤测量结果与病理镜下测量结果中度相关(r=0.576,P<0.001).结论 MRI是乳腺癌新辅助化疗临床疗效评价的可靠方法,其准确性高于B超.
목적 관찰B초급MRI재유선암신보조화료료효평개중적작용.방법 대2007년7월지2008년7월접수신보조화료적85례원발성유선암환자진행전첨성연구,대비분석수술전신보조화료전、화료2주기후、화료4주기후환자적B초、MRI영상학자료,삼조실체류료효평개표준(RECIST)평개료효,병여술후조직병이학검사진행비교.결과 인조환자공85례,균완성4주기신보조화료.MRI평고완전완해(CR)자0례,부분완해(PR)자56례,질병은정(SD)자27례,질병진전(PD)자2례;B초평고CR자0례,PR자52례,sD자31례,PD자2례.MRI급B초대신보조화료후잔여종류검측적양성예측치균위94.1%.기중신보조화료후잔여종류최대경선MRI측용결과여병리경하측량결과고도상관(r=0.783,P<0.05),B초대잔여종류측량결과여병리경하측량결과중도상관(r=0.576,P<0.001).결론 MRI시유선암신보조화료림상료효평개적가고방법,기준학성고우B초.
Objective To evaluate the role of breast B ultrasonography and magnetic resonance imaging in assessing the tumor response to neoadjuvant chemotherapy in breast cancer. Methods Eighty-five patients with breast cancer diagnosed by core needle biopsy received neoadjuvant chemotherapy entered this prospective study. Breast B ultrasonography and dynamic enhanced MRI was performed before chemotherapy induction, after the second course and the fourth course of chemotherapy prior to the surgery. Clinical evaluation was made through the tumor reduction measured by B ultrasonography and MRI, based on the response evaluation criteria in solid tumors (RECIST). Results Measured by dynamic enhanced MRI, 56 patients got partial response (PR), 27 got stable disease (SD) and 2 got progressive disease (PD), none complete response (CR). Measured by B uhrasonography, 52 patients got PR, 31 got SD, 2 got PD, no CR. Residual tumor size after chemotherapy on MRI correlated well with post-operative pathologic findings (r =0. 783,P <0. 05), and B ultrasonography correlated moderately with microscopic findings (r =0. 576, P<0.001). Conclusion Dynamic enhanced MR1 is a reliable method to evaluate tumor response to neoadjuvant chemotherapy in breast cancer.